Wegovy

News

Semaglutide heart benefits may go beyond weight loss

New data suggests that the benefits of Novo Nordisk’s GLP-1 agonist semaglutide in preventing cardiovascular diseases may not simply be a result of weight loss.

News

Wegovy sales double, as starting restrictions start to lift

Novo Nordisk’s breakneck sales growth has continued in the first quarter of this year with a 24% increase that was helped by a doubling in turnover of obesity blockbuster Wegovy

News

EMA finds no suicide risk with GLP-1 diabetes, obesity drugs

There is no evidence of an increased risk of suicidal or self-injurious thoughts and actions with GLP-1 agonists used to treat diabetes and obesity, according to the EU me

News

Heart claims unlock Medicare coverage of obesity drugs

Medicare has loosened restrictions on the reimbursement of obesity drugs, thanks to clinical data showing they can improve cardiovascular outcomes, but their price could b

News

FDA clears Wegovy’s label to include heart health benefits

Novo Nordisk’s Wegovy has been given a first-in-class approval by the FDA to reduce the risk of serious cardiovascular conditions in people who are overweight or obese.

News

Novo Nordisk’s oral amycretin tops Wegovy in obesity trial

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling

Semaglutide heart benefits may go beyond weight loss

Wegovy sales double, as starting restrictions start to lift

EMA finds no suicide risk with GLP-1 diabetes, obesity drugs

Heart claims unlock Medicare coverage of obesity drugs

FDA clears Wegovy’s label to include heart health benefits

Novo Nordisk’s oral amycretin tops Wegovy in obesity trial

Praxis soars on rare childhood epilepsy trial data

How to meet your physicians where they are online

Wegovy

Editor's Picks